

# Lu Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3315208/publications.pdf>

Version: 2024-02-01

21  
papers

5,629  
citations

566801

15  
h-index

676716

22  
g-index

25  
all docs

25  
docs citations

25  
times ranked

9291  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic significance of postsurgery circulating tumor <scp>DNA</scp> in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 1014-1026.	2.3	77
2	Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer. <i>ELife</i> , 2021, 10, .	2.8	12
3	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003620.	3.9	88
4	Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 423-429.	1.4	30
5	A multimodality test to guide the management of patients with a pancreatic cyst. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	129
6	Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. <i>JAMA Oncology</i> , 2019, 5, 1710.	3.4	383
7	The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. <i>International Journal of Cancer</i> , 2019, 145, 540-547.	2.3	15
8	Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1118.	3.4	152
9	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019, 68, 663-671.	6.1	234
10	A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3518-3518.	0.8	5
11	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.	6.0	1,872
12	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	178
13	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. <i>ELife</i> , 2018, 7, .	2.8	118
14	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3516-3516.	0.8	19
15	Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16206-e16206.	0.8	4
16	Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. <i>Science</i> , 2017, 355, 1330-1334.	6.0	803
17	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10202-10207.	3.3	438
18	The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3521-3521.	0.8	11

#	ARTICLE	IF	CITATIONS
19	Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer.. Journal of Clinical Oncology, 2017, 35, 4101-4101.	0.8	9
20	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine, 2016, 8, 346ra92.	5.8	1,036
21	The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.. Journal of Clinical Oncology, 2016, 34, 3511-3511.	0.8	5